Sorafenib Suppliers & Bulk Manufacturers
Available Forms: Film Coated Tablet
Available Strengths: 200 mg
Reference Brands: Nexavar (EU & US)
Category: Oncology Cancer Care
Sorafenib is available in Film Coated Tablet and strengths such as 200 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Sorafenib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Sorafenib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Product Description: Sorafenib Tablets 200 mg are a key oncology treatment used in the management of advanced cancers such as hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma refractory to radioactive iodine. As a multikinase inhibitor, Sorafenib targets tumor cell proliferation and angiogenesis, making it effective in slowing cancer progression. Approved in both the U.S. and EU under the brand name Nexavar, with multiple generic versions available, Sorafenib is a vital product for pharmaceutical B2B distribution. Available in 200 mg film-coated tablets, it meets global oncology standards and supports hospitals and cancer centers in advanced cancer care.
Frequently Asked Questions
Related Products
Atezolizumab
Strength: 1200 mg/20 mL
Form: Intravenous infusion
Reference Brands: Tecentriq® (EU & US)
View Details
Durvalumab
Strength: 120 mg/4 mL, 500 mg/10 mL
Form: Injection
Reference Brands: Imfinzi® (US & EU)
View Details
Sunitinib
Strength: 12.5 mg, 25 mg, 37.5 mg, 50 mg
Form: Tablet
Reference Brands: Sutent® (EU & US)
View DetailsQuick Response Guaranteed | Verified Suppliers